Breaking News

HHS warns vaccine makers over pricing; how a key Senate committee plans to regulate PBMs

July 13, 2023
Pharmalot Columnist, Senior Writer
Rogelio V. Solis/AP

STAT+ | HHS leader to vaccine makers: Set 'reasonable' prices for your next round of Covid-19 vaccines

Becerra's letter about Covid-19 vaccines comes after Pfizer and Moderna were accused of price gouging for their shots.

By Ed Silverman


FDA approves first over-the-counter birth control pill

The FDA has approved the first over-the-counter birth control pill, a medicine called Opill made by Perrigo.

By Ed Silverman


STAT+ | How a key Senate committee is planning to regulate pharmacy benefit managers

A key Senate health care panel has developed a plan to tackle reforms to middlemen known as pharmacy benefit managers.

By Rachel Cohrs



SEBASTIEN BOZON/AFP via Getty Images

STAT+ | Roche shortens delivery time for multiple sclerosis drug from hours to minutes in trial

The company showed delivering its drug, Ocrevus, as a 10-minute injection worked just as well as an IV infusion that takes hours to deliver.

By Jonathan Wosen


Listen: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

STAT's Megan Molteni joins us to explain the evolving science suggesting that products like Wegovy could be treatments for human desire.

By Damian Garde and Meg Tirrell and Adam Feuerstein


STAT+ | Caribou posts encouraging durability results on its off-the-shelf CAR-T therapy

The new data move the treatment closer to the benchmarks set by more established, patient-specific CAR-T therapies.

By Adam Feuerstein


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments